| INTRODUCTION
Autoimmune encephalitis with antibodies against leucinerich glioma-inactivated protein 1 (LGI1) is a rare inflammatory condition mainly targeting the limbic areas of the brain. Typical manifestations of the disease are subacute onset of progressive disturbance in memory and behavior, seizures, and hyponatremia. [1] [2] [3] Faciobrachial dystonic seizure (FBDS)
is very specific to the disease, and antiepileptic drugs (AEDs) have limited efficacy in controlling FBDS and other seizures. 2, 4 Rationale for the use of AEDs in treating anti-LGI1
encephalitis include a certain degree of seizure-suppressing effects until immunotherapy effectively ameliorates seizure activity 2, 4, 5 and the risk of withdrawal seizures occurring before complete remission of disease activity. However, a previous study raised the possibility that patients with FBDS are more vulnerable to adverse cutaneous drug reaction (ACDR) than the general population. 2 The refractoriness of FBDS to AEDs may lead to trials of multiple AEDs and thereby increase the risk of ACDR. However, it is also possible that patients with anti-LGI1 encephalitis per se are vulnerable to ACDR. A strikingly strong association between anti-LGI1 encephalitis and specific human leukocyte antigen (HLA) subtypes DRB1*07:01-DQB1*02:02 and DRB4 recently identified by two independent research groups 6, 7 escalates the suspicion of the latter, considering the associations of HLA alleles with ACDR. Although AED is frequently used to control seizure in patients with anti-LGI1 encephalitis, the safety of the AEDs in this disorder has not been well established. Therefore, we investigated the adverse drug reactions (ADRs) to AEDs in anti-LGI1 encephalitis.
| MATERIALS AND METHODS
The study population consists of patients who were diagnosed with autoimmune encephalitis at three hospitals in South Korea, Seoul National University (SNU) Hospital, SNU Bundang Hospital, and Seoul Metropolitan Government-SNU Boramae Medical Center, from October 2012 to September 2016. Diagnosis of autoimmune encephalitis was made based on the clinical features of limbic encephalitis and synaptic autoantibodies detected in serum or cerebrospinal fluid. 8, 9 Autoantibodies to N-methyl-D-aspartate receptor, LGI1, contactin-associated protein-like 2, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 1 and 2 receptors, and γ-aminobutyric acid type B receptor were tested using a commercially available cell-based immunofluorescence assay (Euroimmun, Lübeck, Germany). We reviewed clinical records of the patients, which include the demographic profile, seizure and other clinical manifestations, laboratory and imaging findings, the use of AEDs and immunotherapeutic agents, treatment period, and ADRs. Patients who did not received AEDs were excluded from the analysis. Appreciably harmful medical conditions manifesting in the patients were regarded as ADRs to AEDs when the treating physician changed the medication upon suspicion of ADR and the condition was resolved after discontinuation of the AED. Dose-dependent adverse effects that were reversible by dose readjustment (eg, dizziness and somnolence) and did not result in discontinuation of the AED were not considered ADRs in this study. For statistical analysis, either Fisher exact test or Wilcoxon rank-sum test was used as appropriate, and P < .05 (two-tailed) was considered significant. The study was approved by the institutional review board of SNU hospital, and written informed 
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| 109 consent was obtained from the patients or their legal representatives.
| RESULTS
Among 21 patients who were diagnosed with anti-LGI1 encephalitis, AEDs were administered to 20 (95.2%) for seizure control. The median follow-up period was 18.5 months (interquartile range = 7.5-39.5 months). Clinical manifestations of the study population are summarized in Table 1 . Levetiracetam was the most frequently used AED in this population, followed by oxcarbazepine ( Table 2) . The most frequent ADR to AED was ACDR, which was reported in one-half of the patients. Nine patients suffered from maculopapular rash, including one with drug rash with eosinophilia and systemic symptoms and another with eczema. AEDs that were discontinued due to suspicion of ACDR included oxcarbazepine, lamotrigine, phenytoin, carbamazepine, and levetiracetam (Table 2) . Among the three patients who discontinued lamotrigine, two discontinued oxcarbazepine at the same time, and the other discontinued levetiracetam concurrently. One of the two patients who discontinued phenytoin also discontinued carbamazepine simultaneously on detection of ACDR. Although causative AEDs are unclear in these events, there were five patients in whom ACDR was solely attributable to oxcarbazepine and one patient with phenytoin-associated ACDR. Aromatic AEDs were among the causative AEDs for all patients with ACDR.
The median time between initiation of the suspected AED and the occurrence of ACDR was 28 days (interquartile range = 14-33). Among the nine patients who showed skin rash, ACDR occurred after the completion of corticosteroid therapy in five patients and four of them showed ACDR between 9 and 12 days after tapering off of corticosteroids. Three were not using a corticosteroid during the period between the initiation of the suspected AED and the occurrence of ACDR. ACDR was detected soon after the initiation of a corticosteroid in another patient. Two to seven AEDs were tried in these patients, and the number of AEDs was not associated with the occurrence of ACDR (P = .67). The frequency of ACDR was not different between the patients with (n = 6) and without FBDS (n = 4; 46% vs 57%, P = 1.00). There was a clear difference in the frequency of ACDR between patients with anti-LGI1 encephalitis and patients with other neuronal surface antibodies who were diagnosed with autoimmune encephalitis in the same period (P < .0001; Table 3 ).
Hyponatremia was found in 14 (70%) of the patients (Table 1) , including patients in whom hyponatremia developed (n = 3) or was aggravated (n = 2) after the administration of oxcarbazepine. Although most cases of hyponatremia were mild and/or manageable without changing the AED, oxcarbazepine was discontinued in two patients due to severe hyponatremia (<120 mmol/L).
Six patients (30%) discontinued levetiracetam for psychiatric manifestations including irritability/aggressive behavior (n = 4), insomnia (n = 1), and depressive mood (n = 1). Steroid psychosis was also suspected in one of these patients because the symptom did not improve until subsequent tapering off of corticosteroids. One patients showed improvement of aggressive behavior by dose reduction.
| DISCUSSION
This study demonstrated that ACDR occurs frequently in anti-LGI1 encephalitis, which was previously reported only for patients with FBDS manifestation. 2 In addition, neither FBDS nor the number of AEDs was associated with greater frequency of ACDR. It is known that genetic variations in HLA plays a role in AED-associated ACDR. Therefore, findings of a highly homogeneous HLA type in patients with anti-LGI1 encephalitis 6, 7 could be an explanation for the high frequency of ACDR in anti-LGI1 encephalitis. We followed patients with anti-LGI1 encephalitis for a sufficient period of time to observe the occurrence of ACDR after the discontinuation of corticosteroids. All the patients experiencing ACDR in our study received an aromatic AED, and more than one-half of the aromatic AED users had ACDR. The prevalence of ACDR attributed to AED in our population is substantially higher than the prevalence of ACDR to AED in the general population (5%-15%), 10, 11 and also higher than the prevalence observed in both patients with epilepsy after encephalitis/encephalopathy (23.9%) 12 and the non-LGI1 group.
Hyponatremia is a symptom of anti-LGI1 encephalitis and thus cannot easily be distinguished from hyponatremia arising from ADRs to AEDs such as carbamazepine and oxcarbazepine. These drugs may also exacerbate the hyponatremia caused by the disease. Along with the high risk of ACDR, hyponatremia could be an additional reason to avoid these agents in patients with anti-LGI1 encephalitis.
Levetiracetam is an AED that complicates psychiatric symptoms in anti-LGI1 encephalitis, which are often caused by the underlying disease pathology and/or highdose corticosteroid therapies that can evoke adverse psychiatric effects. Levetiracetam was frequently the suspected agent that precipitated or aggravated psychiatric symptoms in the study population. It is known that temporal lesions are associated with increased risk of AED-induced psychotic disorders. 13 Although psychiatric symptoms were not always clearly attributable to levetiracetam in this study population, our results indicated that caution with respect to psychiatric side effects should be taken when choosing an AED for anti-LGI1 encephalitis. ADR is often the single most important consideration in selecting an AED. Nonaromatic AEDs are more desirable according to our findings and previous studies indicate that this is generalizable beyond Asian populations. 2, 7 Hyponatremia and psychiatric adverse effects also need to be considered in selecting AEDs for patients with anti-LGI1 encephalitis. We note that our study comprises a small number of patients, and there was unevenness in AED selection, which limited our evaluation of ADRs especially to those AEDs that were not frequently used in our population. Therefore, future studies with more patients and observations are warranted to establish guidelines for the use of AEDs in anti-LGI1 encephalitis. Moreover, hippocampal sclerosis is observed in around one-half of patients with anti-LGI1 encephalitis on follow-up imaging according to recent studies 14, 15 ; proper use of AEDs in such patients also needs investigation.
